Macheal Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 21 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -63.31%
(FY 2023)
- Profit -55.02%
(FY 2023)
- Ebitda -18.66%
(FY 2023)
- Net Worth 5.84%
(FY 2023)
- Total Assets -29.61%
(FY 2023)
About Macheal Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Aman Mohan, Payal Mohan, and Vipul Mohan serve as directors at the Company.
- CIN/LLPIN
U24231GJ2003PLC042549
- Company No.
042549
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- LocationNa, Gujarat
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Macheal Laboratories Limited offer?
Macheal Laboratories Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antibiotic Tablets & Capsules, Azithromycin Tablets, Antibiotic Injection, Piperacillin Tazobactam Injection.
Who are the key members and board of directors at Macheal Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aman Mohan  | Additional Director | 02-Apr-2018 | Current |
| Payal Mohan | Whole-Time Director | 18-Oct-2007 | Current |
| Vipul Mohan | Whole-Time Director | 18-Oct-2007 | Current |
Financial Performance of Macheal Laboratories.
Macheal Laboratories Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 63.31% decrease. The company also saw a substantial fall in profitability, with a 55.02% decrease in profit. The company's net worth moved up by a moderate rise of 5.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Macheal Laboratories?
In 2023, Macheal Laboratories had a promoter holding of 97.66% and a public holding of 2.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Macheal Laboratories?
Unlock and access historical data on people associated with Macheal Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Macheal Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Macheal Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
